IMPORTANCE Solid-organ transplant recipients (OTRs) are at an increased risk for skin cancer. Prior studies have demonstrated a reduced incidence of skin cancer in renal OTRs treated with sirolimus. However, little information exists on the use of sirolimus for the prevention of skin cancer in nonrenal OTRs or those already diagnosed as having a posttransplant cancer.
of CSCC is estimated to be 65 to 250 times more frequent in OTRs compared with the general population. 8 Several studies [9] [10] [11] have also shown a 28-to 49-fold increase in the incidence of non-Hodgkin lymphoma and a 400-to 500-fold increase in the incidence of Kaposi's sarcoma in OTRs compared with the general population. Advances in immunosuppressive medications have been responsible for considerable improvements in acute and chronic organ rejection and the life expectancy of OTRs. However, the risk for cancer in OTRs is related to the level of immunosuppression. A high risk for malignant neoplasms has been observed for heart and lung OTRs who receive high levels of immunosuppressive therapy, whereas a lower risk has been observed in kidney and especially liver OTRs who require lower levels of immunosuppressive medications. [12] [13] [14] Multiple-drug regimens appear to be associated with the highest risk. 15 Conversely, mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce the growth and proliferation of tumor cells. 16, 17 Recent clinical studies have demonstrated a reduced incidence of skin cancer in kidney OTRs treated with sirolimus as first-time therapy 18, 19 and those who switch therapy from calcineurin inhibitors to sirolimus. [20] [21] [22] Studies examining the effect of mTOR use on the risk for subsequent cancer formation in OTRs who already have been diagnosed as having a posttransplant cancer are limited. Because cancer formation is a major reason for conversion to mTOR therapy, data on the reduction of cancer risk in patients with a history of cancer have high clinical relevance. In addition, data regarding the impact of conversion to mTOR inhibitor therapy in nonrenal OTRs are limited. The present study was undertaken to assess the risk for subsequent cancer in a mixed-organ cohort of OTRs diagnosed as having various posttransplant cancers and to compare subsequent cancer risk by use vs nonuse of mTOR inhibitors.
Methods

Identification of Study Cohort
We searched . Only 6 patients (1.8%) underwent mixed-organ transplants, including 1 patient with a heart-lung transplant, 3 patients with liver-kidney transplants, and 2 patients with heart-kidney transplants.
Sirolimus was the only mTOR inhibitor drug used in the cohort because other mTOR inhibitors were not yet in use during the study period. Median follow-up time was 40 (range, 4-143) months in the sirolimus-treated group (n = 97) and 36 (range, 2-245) months in the non-sirolimus-treated group (n = 232). The median time to the development of the first posttransplant cancer (index cancer) was 42 (range, 3-341) months. No difference in age (P = .55), sex (P = .51), race (P = .51), history of pretransplant skin cancer (P = .21), type of index posttransplant cancer (P = .83), history of posttransplant infections (P = .06), or induction therapy (P = .78) was observed between the sirolimus-treated and non-sirolimus-treated patients. A higher proportion of kidney (62 of [11.6%] ; P = .03). We found no significant difference in the proportion of heart OTRs (P = .19) and multiorgan OTRs (P = .68) in the sirolimus-treated vs non-sirolimus-treated groups. No significant difference in azathioprine (P = .83), prednisone (P = .11), or cyclosporine (P = .62) use during the study period was observed between the sirolimus-treated vs non-sirolimus-treated groups. However, compared with the non-sirolimus-treated group, a higher No significant difference in death from posttransplant infection (P = .25) or rejection (P = .33) was observed among c For all OTRs, includes lung cancer (n = 2), brain cancer (n = 2), pancreatic cancer (n = 1), rectal cancer (n = 1), renal cancer (n = 2), thyroid cancer (n = 2), B-cell lymphoma (n = 1), mesothelioma (n = 1), ovarian cancer (n = 1), bladder cancer (n = 1), and breast cancer (n = 1). For nonrenal OTRs, includes lung cancer (n = 1), brain cancer (n = 1), mesothelioma (n = 1), ovarian cancer (n = 1), and bladder cancer (n = 1). d Includes local recurrence, nodal metastasis, distant metastasis, or death from cancer. 93  57  40  25  17  12  8  7  232  69  54  39  27  16  8  5  3  2  97 No sirolimus treatment Sirolimus treatment
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Cumulative incidence rates for a second posttransplant cancer by sirolimus treatment. P value is calculated using the Gray test. sirolimus-treated vs non-sirolimus-treated OTRs in the overall cohort. A 9% reduced risk for overall death was observed among sirolimus-treated patients in the overall cohort; however, the difference did not reach statistical significance (27.1% vs 36.6%; P = .10). The cumulative incidence rates of skin cancer at 1, 3, and 5 years after the index posttransplant cancer were 9.3%, 20.6%, and 24.7%, respectively, in the sirolimus-treated group vs 17.7%, 31.0%, and 35.8%, respectively, in the non-sirolimustreated group, thus demonstrating a lower risk for skin cancer with sirolimus treatment (Gray test, 5.97; P = .02) (Figure 2) . Because skin cancer was the major driver of second posttransplant cancers in this cohort, competing risks regression analysis was focused on identifying independent risk factors associated with second skin cancer formation.
Results of the univariate analysis of risk factors associated with postindex skin cancer formation cancer are shown in eTable 2 in the Supplement. Multivariate analysis to identify predictors of postindex skin cancer formation demonstrated that history of pretransplant skin cancer (subhazard ratio [SHR], 2.1; 95% CI, 1.2-3.7; P = .02), history of the index posttransplant cancer being skin cancer (SHR, 5.5; 95% CI, 2.5-6.4; P < .001), and sirolimus treatment (SHR, 0.6; 95% CI, 0.4-0.9; P = .03) were significantly associated with formation of postindex skin cancer. The same factors were associated with postindex skin cancer formation when multivariate analysis was limited to nonrenal OTRs (history of pretransplant skin cancer [SHR, 2.7; 95% CI, 1.5-5.0; P = .001], history of the posttransplant index cancer being skin cancer [SHR, 3.9; 95% CI, 1.9-7.9; P < .001], and sirolimus treatment [SHR, 0.5; 95% CI, 0.3-1.1; P = .08]), although the association with sirolimus treatment did not reach statistical significance.
Discussion
In this 2-center mixed-organ cohort of OTRs diagnosed as having posttransplant cancer, 39.5% of patients developed a second posttransplant cancer. Most of the subsequent cancers (88.5%) were skin cancers; therefore, only factors associated with subsequent skin cancer formation could be determined. A history of skin cancer (before or after the transplant) was associated with a higher risk for subsequent skin cancer formation, and the use of sirolimus was protective, with a 40% adjusted reduction in risk (SHR, 0.6; 95% CI, 0.4-0.9) in the overall cohort. When multivariate analysis was limited to the 146 nonrenal OTRs (44.4% of the cohort), the same independent factors were associated with subsequent skin cancer development with sirolimus exposure (P = .08), although not significantly so owing to reduced statistical power. No increase in rejection or mortality was associated with sirolimus use in the overall cohort. Patients with a history of skin cancer (before or after transplant) had a 2-to 5-fold higher risk for subsequent skin cancer formation consistent with the results of prior studies. 24, 25 Prior studies 20, 26, 27 have shown a reduction in skin cancer risk in OTRs treated with sirolimus. However, these studies have been limited to patients undergoing renal transplant. To our knowledge, this study is the first to show a reduction of skin cancer risk in a cohort of patients with various types of organ transplants and a history of posttransplant cancer. This risk reduction in skin cancer formation was present even after adjusting for prior skin cancer, which predisposes patients to subsequent skin cancer formation. Thus, even for patients who have already had difficulty with skin cancer formation, mTOR inhibition appears to be of benefit. No difference in cancer outcomes was observable between sirolimus-treated and non-sirolimus-treated groups because poor outcomes were rare. A recent study 25 found that sirolimus exposure was not associated with a reduction in incident CSCC after transplant in a mixed-organ cohort of OTRs. Our study is different in that it examines the risk for skin cancer formation in a mixed-organ cohort of OTRs who had already developed some form of posttransplant malignant neoplasm. This patient population had already demonstrated a propensity toward cancer formation and was at higher risk for developing skin cancer than the general OTR population. 28,29 Our data support consideration of this subset of OTRs who develop posttransplant cancer for sirolimus chemoprevention. Our results indicate a 40% reduction in the risk for a second skin cancer even after adjusting for a history of skin cancer. In addition, a recent meta-analysis 24 showed an increase in overall mortality with sirolimus use, but mortality was not elevated in low-dose sirolimus studies. 24 The present study found a 9% reduction in mortality in the sirolimus group (although it did not reach statistical significance, at P = .10). In many early trials, 24 patients underwent immediate conversion to mTOR inhibition therapy, and high doses were used. At our institution, patients undergo gradual conversion from traditional regimens to mTORbased treatment, and maintenance therapy tends to consist of relatively low doses of sirolimus (mean [SD] dose, 2.2 [1.4] mg), with a potential for fewer mTOR-related adverse effects. Our study has limitations. The study was underpowered to assess the effect of mTOR inhibitor use on cancers other than skin cancer because other cancers were rare. The study was nonrandomized; thus, other factors that were associated with cancer formation may have driven the choice of mTOR use or nonuse, although this seems unlikely. Conversion to mTOR inhibition therapy is inevitably accompanied by discontinuation of therapy with or dose reduction of other immunosuppressive agents; therefore, the differential effect on cancer formation of mTOR treatment initiation vs withdrawal of other agents cannot be ascertained. However, this effect reflects real-world management choices, so the overall impact of mTOR conversion, including the effects of sparing other drugs, has clinical relevance. Finally, the study data are derived from a retrospective electronic medical record review, and adherence to mTOR inhibition and other immunosuppressive therapies could not be assessed. However, adherence should not differ substantially between mTOR and non-mTOR groups; therefore, this lack should have little effect on our results and conclusions.
